BILA 2157 BSAlternative Names: BILA 2157
Latest Information Update: 16 Oct 2003
At a glance
- Originator Boehringer Ingelheim (Canada)
- Class Antihypertensives
- Mechanism of Action Renin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hypertension